SWOG clinical trial number
S0424

Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men

Closed
Phase
Accrual
100%
Abbreviated Title
Molecular Epidemiology
Activated
10/01/2005
Closed
03/15/2011
Participants
NCORP, Members, Medical Oncologists, Pathologists, ECOG, NCCTG, RTOG, CALGB, CTSU

Research committees

Lung Cancer
Molecular Epidemiology

Eligibility Criteria Expand/Collapse

Pts must have newly diagnosed, primary, histologically confirmed Stage I, II, IIIA or IIIB (T4 or N3, excluding patients w/ malignant pleural effusion) NSCLC; Pts w/effusion are eligible if: a)fluid tapped is benign cytology and all physicians concur that it is from a benign etiology, b) fluid present after mediastinoscopy or thoracotomy, but not before, c) fluid deemed too small to tap under CT or U/S guidance; May be registered concurrently to a therapeutic study but not required to be on a therapeutic study; Must have tumor block/slides available and willing to provide tissue and blood sample for testing; Must have specific tissue specimens available as outlined in Section 4.2; Able and willing to complete the Lung Cancer Epidemiology Questionnaire and able to read and understand English; Must be identified and registered w/in 120 days of diagnosis; Must be willing to provide smoking history; Pts must not have diagnosis by cytology alone; Pts must not have malignant pleural effusion; Pts must not have other prior malignancy except for treated basal cell (or squamous cell) skin ca or in situ cervical ca; Pts must not have prior systemic chemotherapy or RT for cancer; Pts must not have pericardial effusions-if CT shows effusion then a negative echo must be confirmed OR effusion must be from a recent sx or other documented benign cause. NOTE: Pts registered concurrently to therapeutic trials must have blood and tissue obtained PRIOR to administration of ANY therapeutic agent(s).

0.5 Cancer Control Credits

Publication Information Expand/Collapse

2024

Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): survival differences in the context of race, gender and smoking

P Mack;S Isa;M Hsieh;Y Koh;J Moon;A Tamiya;M Redman;K Albain;K Kelly;C Ambrosone;JE Gray;A Kubo;D Gandara;P Lara;T Kawaguchi ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 8036)

2018

Smoking, sex and non-small cell lung cancer: examination of steroid hormone receptors in lung tumor tissue in SWOG S0424

TD Cheng;A Darke;M Redman;G Zirpoli;W Davis;R Ondracek;W Bshara;AR Omilian;R Kratzke;JR Molina;JM Kolesar;Y Chen;R MacRae;J Moon;P Mack;D Gandara;K Kelly;R Santella;K Albain;C Ambrosone Journal of the National Cancer Institute Jul 1;110(7):734-742; Jan 13. doi: 10.1093/jnci/djx260. [Epub ahead of print]

PMid: PMID29346580 | PMC number: PMC6037104

Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)

K Albain;A Darke;P Mack;M Redman;T-YD Cheng;J Moon;W Holland;A Borczuk;CH Chay;PT Morris;E Vallieres;R Kratzke;JR Molina;J Kolesar;Y Chen;R MacRae;S Matsumoto;M Reid;G Zirpoli;W Davis;R Ondracek;W Bshara;A Omilian;D Gandara;K Kelly;R Santella;C Ambrosone WCLC IASCLC Annual Meeting (Sept 23-26, 2018, Toronto CAN), oral

2017

Steroid hormone receptor protein expression by gender and smoking in non-small cell lung cancer:SWOG S0424

T-Y Cheng;A Darke;M Redman;G Zirpoli;W Davis;R Payne Ondracek;W Bshara;R Kratzke;JR Molina;JM Molina;Y Chen;RM MacRae;J Moon;P Mack;D Gandara;K Kelly;R Santella;KS Albain;C Ambrosone Modern Pathology Vol 30, Issue S2 (February 2017), p. 474A, abst. 1907; USCAP Annual Meeting 2017 (March 4-10, 2017, San Antonio, TX), poster

2010

KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424

PC Mack;M Redman;K Chansky;S Matsumoto;W Holland;P Lara;C Ambrosone;DR Gandara Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013); ASCO annual meeting; poster

2009

Biomarkers of polycyclic aromatic hydrocarbon-DNA damage and cigarette smoke exposure

RM Santella;Y-J Zhang;Q Wang;M Redman;M Reid;W Davis;DR Gandara;C Powell;K Albain;C Ambrosone Journal of Thoracic Oncology, 4(9):suppl. 1, abst M39.2, S164 (IASLC 13th World Conf of Lung Cancer, oral presentation);

Molecular epidemiology of lung cancer

CB Ambrosone Journal of Thoracic Oncology 4(9):suppl 1, abst. M38.5, S163 (oral pres., IASLC 13th World Conf of Lung Cancer)

Role of EGFR pathway activation in never smoking patients with lung cancer

PC Mack Journal of Thoracic Oncology 4(9):suppl 1, abst. M39.3, S164 (oral presentation, 13th World Conference of Lung Cancer)

2008

Molecular epidemiology to better predict lung cancer risk

M Reid;RM Santella;CB Ambrosone Clinical Lung Cancer 9(3):149-153

PMid: PMID18621624 | PMC number: Review article not within scope of Public Access Policy

Cooperative group research efforts in lung cancer: focus on early stage non-small cell lung cancer

H Wakelee;C Langer;E Vokes;J Schiller;P Bass;N Saijo;A Adjei;F Shepherd;H Choy;DR Gandara Clinical Lung Cancer 9(1):9-15

PMid: PMID18282352 | PMC number: (Reviews are not within the scope of the Public Access )